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Abstract	The aging human population has emerged as a critically important factor in health care, not only
due to the unique physiologic and pathologic processes associated with aging but also because of
the evolution of medical and surgical therapies that have increased quality and quantity of life. Heart
failure is a disease found most commonly among older populations in whom it is associated with high
morbidity and mortality. Heart failure disproportionately affects the elderly, and it stands to reason
that the most terminal stage, known as advanced heart failure (AHF), is more common among the
elderly. Despite limited data, treatment options for AHF patients, including heart transplantation and
left ventricular assist device (LVAD) therapy, have demonstrated improved quality and quantity of life.
Similarly, a well-structured palliative care program may offer symptom relief and social support without
the need for high-risk surgical options. Furthermore, as the therapeutic window (risk/benefit ratio)
is narrower among elderly patients, the potential for positive outcomes from AHF options must be
carefully evaluated together with patient-specific risks in the context of palliative care discussions.
Therefore, the decision to leverage these options must be balanced with not only age, but also frailty,
comorbidities, and cognition, functional, social and nutritional status to determine the right candidates
for each therapy. This review strives to inform providers on the relevant considerations when
leveraging AHF options among elderly patients. We conclude by providing a personalized model for
care developed at a large tertiary care hospital that has performed more than 1,600 AHF procedures
(870 heart transplants, 745 LVADs). (J Patient Cent Res Rev. 2016;3:199-206.)
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Due to improvements in the management of acute and
chronic diseases and the concept of preventive medical
care, the present-day human population is living longer
than any prior generation. The number of people
worldwide who are 60 years or older is expected to
double by 2050 (to 2.4 billion).1 In the United States
alone, there will be 83 million.2 Particularly relevant
to this review, the elderly (defined as age > 70) are the
fastest growing age group in the world and projected to
triple by 2050. Since the majority of health care resources
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and ultimate expenditures are among populations with
chronic diseases (cardiovascular diseases, cancer and
neurodegenerative diseases), and these conditions are
most prevalent among aging populations, all societies
must address the concerns of health and aging.
As cardiovascular diseases disproportionately afflict
the elderly, it is not surprising that the incidence,
prevalence, morbidity and mortality for heart failure
(HF) is highest in this age group.3 Within the next two
decades, the incidence of HF is expected to rise to
700,000 cases annually; this translates to a 46% rise
in prevalence. After age 80, the lifetime risk of HF is
one in five, and once diagnosed, the prognosis is much
worse for both men and women compared with younger
cohorts.4 The number of hospitalizations for HF has
www.aurora.org/jpcrr
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consistently increased over the last 30 years, with half
of readmissions related to HF-associated comorbidities,
polypharmacy and disabilities (which are all more
evident among elderly cohorts).5 The U.S. Centers for
Medicare & Medicaid Services estimates HF costs
at $70 billion by 2030, with 50%–74% attributed to
hospitalization or long-term institutional care.4
Medical and device therapies have evolved to reduce
morbidity and mortality of HF predominantly by
decreasing disease progression. Despite these advances,
HF remains a progressive disease that culminates in greater
functional limitation, more hospitalization and eventual
death. Various definitions have been used to characterize
advanced heart failure (AHF); in general, they encompass
three domains –– severe functional limitations, recurrent
hospitalizations and refractory symptoms –– each
independently associated with high short-term mortality
(based on risk models).6 Approximately 3%–6% of all
patients with chronic HF have AHF, and in the United
States, there are an estimated 200,000 adults with
AHF, most over 70 years old.6-9 Elderly AHF patients
experience multiple hospitalizations over short periods
of time and require escalating therapies, with higher
mortality compared with younger cohorts.4,10
Traditional options advocated for patients with AHF
include heart transplantation (HT), left ventricular
assist device (LVAD) therapy and/or palliative care.
The rational allocation of heart replacement options
(HT or LVAD) among elderly patients requires an
understanding of risk and benefit in the context of
clinical care, disease trajectory and, particularly,
noncardiac comorbidities (renal insufficiency, chronic
lung disease, neuromuscular or cognitive disorders,
nutrition and psychosocial isolation, etc.), including
frailty. Any novel therapeutic interventions must be
balanced with expected risks and benefits that may have
a narrower therapeutic window among older patients.
The discussion may turn from a question of “Can we
perform the intervention?” to rather “Should we perform
the intervention?” Therefore, objective means and
decision tools must be developed to assist providers and
patients in answering these questions.
Heart Transplantation
HT is believed to be the gold standard for patients
with AHF. The International Society of Heart & Lung
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Transplantation (ISHLT) registry published data
demonstrating that in any calendar year there has never
been more than 4,700 heart transplants performed
worldwide, clearly not meeting the aforementioned
rising demand for AHF treatment. The lack of acceptable
organs for donation, as well as societal norms and clinical
practices, have established a general upper age limit for
HT at approximately 65–70 years. It had been accepted
that advanced age adversely affects long-term survival
rates in HT recipients.11-15 However, approximately 1%–
3% of all transplants are still performed in patients at least
70 years old, and several case series have demonstrated
similar intermediate outcomes (at 1 and 3 years) between
older (age > 70) and younger HT recipients. These
patients are obviously highly selected and account for less
than 5% of the total cohorts evaluated.16-20
Extending these observations, Daneshvar et al. found
no statistical difference in survival in patients over 70
compared to a younger cohort up to 10 years after HT.21
Blanche et al. demonstrated that using select older donors
for select older recipients was safe and may offer a unique
strategy for organs that may be declined for younger
recipients,16 while others have advocated marginal
donor hearts as acceptable options for elderly patients.22
Select patients over age 70 who have undergone HT
had lower incidences of allograft rejection, possibly as
a result of natural immunosenescence associated with
aging, thus making them better long-term candidates
for transplant.23 Furthermore, another study24 observed
that elderly patients experienced greater satisfaction
with quality of life (QOL) posttransplant and expressed
less stress and depression after transplant than younger
patients. The same study also found that elderly patients
were more compliant with follow-up medical programs
and treatments than younger patients.24
In contrast to such reports, the most recently published
2015 ISHLT registry data (for approximately 100,000
HT recipients since 1982) documented that survival (by
Kaplan-Meier analysis) among the 818 patients aged
greater than 70 years was inferior to younger patients.25
While this observation lost significance when the same
analysis was restricted to patients in the most recent
transplant analysis era (2009–2013), a multivariable
investigation still found that recipient and donor age
significantly impacted 1- and 5-year post-HT survival.25
Therefore, recent ISHLT guidelines only advocate HT
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in select patients over age 70 in the absence of other
comorbidities known to impact short- and intermediateterm outcomes, including chronic kidney, liver or lung
disease.26 Despite data supporting HT among select
elderly patients, a recent analysis of the United Network
for Organ Sharing (a U.S. registry) found only 1.3% of
total transplants were performed in recipients more than
70 years old.23 Furthermore, since transplant volume
appears to have a high impact on post-HT outcomes,27,28
we would advocate transplantation in elderly patients be
preferentially considered in higher-volume centers.
Evident from these data, HT will never meet the
increasing demand for heart replacement options,
particularly among elderly patients.22,29 As a result,
alternatives to HT for providing cardiac support, such as
LVAD therapy, have been established and are growing
in popularity.
Left Ventricular Assist Device Therapy
Concerns regarding clinical outcomes and the societal
rationing of HT to younger recipients, compounded by
the dramatic, unmet and increasing demand for heart
replacement therapy in elderly AHF patients, has spurred
the development of durable LVAD therapy. While
initially implemented as a strategy to support patients as a
bridge to transplantation, modern continuous-flow LVAD
therapies are now often used as destination therapy. These
LVADs offer the realistic promise of a relatively longterm (1–5 years) form of cardiac support to those who are
either ineligible or do not wish to pursue HT.
Compared with medical therapies, AHF populations
supported with LVAD technologies have twice the
survival rate, better physical functional capacity and
improved QOL metrics.30,31 In 2010, the HeartMate
II LVAD (Thoratec Corp., Pleasanton, CA) was
approved by the U.S. Food and Drug Administration
as destination therapy for its promise of durability and
reduced complications. In previous pivotal trials of
LVAD technologies, the most common indication for
destination therapy was age, and subsequent trials or
registries have dramatically increased the use of LVAD
among elderly patients. Compared with prior iterations
of the Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS),29,32 current data
show a significant rise in both the number of patients
receiving LVAD therapy and an upward shift in those

Review

over age 60 (32% prior to 2010 and 49% in 2014).32
While overall data indicates that age displays a moderate
decrement in survival for those over age 65 (hazard
ratio: 1.36, P<0.0001),33 this registry data is incomplete
and may have selection biases for reporting outcomes.
Besides age, one must also take into consideration that,
compared to younger patients, older cohorts have more
comorbidities and do not have the option of HT, all of
which may generate further bias to registry data.
Several studies have evaluated the application of LVAD
technology in the elderly. Adamson et al.34 described a
single-center experience using HeartMate II in 30 patients
over age 70 (mean 76 ± 3.9 years). Comparing this cohort
with a younger cohort (mean 56.7 ± 14.3 years), older
age was associated with nearly identical hospital length
of stay, 1- and 2-year survival, and major complications
(bleeding, infection, arrhythmia, renal failure, right
heart failure and stroke). Authors also highlighted center
experience and the rigorous evaluation by a dedicated
multidisciplinary health care team to assess and optimize
neurologic, nutritional, psychosocial and renal function
as factors for successful outcomes.34 Using the largest allpayer database in the United States, Kilic et al.35 observed
comparable mortality, with no independent impact of
age on inpatient mortality, when comparing elderly
patients (age > 70, n=1,472) to a younger group (age
60–69, n=2,787) supported with continuous-flow LVAD.
Somewhat contradictory data was published by Atluri et
al.,36 who examined the INTERMACS national registry
from 2006 to 2012 and similarly dichotomized patient
groups into age > 70 (n=590) and age < 70 (n=4,439).
They found that despite higher INTERMACS profiles
(indicating less severe illness at time of enrollment),
comparable heart bypass time and comparable length of
stay, 2-year survival was lower in the older cohort (63%
vs 71%, P<0.001). In a multivariable Cox proportional
hazard analysis, age was an independent predictor of
mortality (hazard ratio: 1.45 [95% confidence interval:
1.13–1.85], P=0.003). In this analysis, the older group
was statistically more likely to experience a stroke (2.3%
vs 0.9%, P=0.01) or gastrointestinal bleeding (19.8%
vs 13.4%, P<0.001), but had much lower incidence of
driveline-associated infection (5.7% vs 12.6%, P<0.001).
Finally, Grady et al. examined the impact of age (n=493
> 70 years, n=977 < 70 years) among patients enrolled
in INTERMACS and found that despite a higher selfreported QOL prior to LVAD implant compared to
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younger cohorts, older adults demonstrated equivalent
gains in QOL metrics 1 year after implantation.37 While
lower QOL score and rehospitalization after LVAD were
important variables in subsequent QOL scores, age did
not influence this metric.
Combining these data, the landscape for using LVAD
technologies appears promising for older individuals with
AHF. The best results seem to be among older patients
evaluated by programs with a high level of clinical
experience (by volume and outcomes) that utilize a
dedicated multidisciplinary team and select patients with
fewer comorbidities or more factors that optimize patient
outcome. Anticipated survival is comparable to younger
cohorts, and QOL gains are sustained.
Although the use of LVAD as destination therapy for
older patients with AHF is promising and increasing,
there are an increasing number of elderly patients with
AHF who are not candidates for HT or an LVAD or who
do not wish to pursue either of these surgical options.
The objective of these patients’ care should focus on
how to improve QOL through palliative care.
Palliative Care
In the past, palliative care was considered as an adjunctive
HF treatment that should be initiated only when other
standard HF treatment options proved unsuccessful.
Now, more and more providers and health advisory
organizations have begun to realize the importance
of early use of palliative care in the management of
AHF. Accordingly, most major cardiovascular medical
societies have issued guidelines recommending
the incorporation of prognostic stratification and a
palliative care evaluation (with discussion on goals of
care) for treatment of patients with HF.38 Despite these
recommendations and the creation of a recognized
palliative care subspecialty, the discussion tool and
subsequent services have been underutilized.39 One
study revealed that only 6% of patients hospitalized for
HF received palliative care consultation in spite of the
fact that nearly 60% of patients studied were at elevated
risk of mortality.40 These findings are consistent with
others who have examined palliative care consultation
among HF and noncancer medical populations.41,42
Palliative care must be integrated in the assessment and
evaluation of elderly patients with AHF. In many cases,
LVAD or HT is not medically or surgically viable for
202 JPCRR • Volume 3, Issue 4 • Fall 2016

these patients, and some patients who understand their
prognosis still choose not to pursue these options. At
this point, a goals-of-care discussion should focus on
managing physical symptoms and the psychological
well-being of both the patient and family. This discussion
is often initiated by the AHF cardiologist or physician
most familiar with the patient’s care and illness trajectory.
Frequently, a palliative care specialist is incorporated to
assist in the mobilization of resources and further define
specific goals toward the end of life in the context of the
patient’s psychosocial support and spiritual belief systems.
Treatment goals are often framed in the context of patient
autonomy, dignity and choice of physical location (home
or facility). While age is often an important factor for
palliative care referral, only after a thorough evaluation
of all reasonable options in line with patient preference
should end-of-life therapy be initiated.39
Frailty and Advanced Heart Failure Therapy
Options
Frailty, particularly physical frailty, is a condition often
recognized by the provider but difficult to quantify;
however, it is often one of the most important factors
influencing the answer to the question “Should we pursue
AHF surgical options?” The traditional definition of
frailty encompasses “a medical syndrome with multiple
causes and contributors characterized by diminished
strength, endurance, and physiologic function that
increases an individual’s vulnerability for developing
increased dependency and/or death.”43 Frailty may not
be a disease but a natural result of aging.44 The physical
definition of frailty is more often observed in both the
elderly and HF populations than among the general
population.45 In the Cardiovascular Health Study,46
almost one in four adults between age 65 and 84 were
frail, and the prevalence of frailty increased with age
–– reaching 44% in adults 85 years or older.47 However,
frailty also may be induced and/or exacerbated by
the burden of cardiac disease and is associated with
negative outcomes.48 When examined in the context of
coronary artery disease, acute coronary syndromes and
percutaneous coronary intervention, frailty has been
extensively demonstrated to be a prognostic indicator of
adverse cardiac events, rehospitalization and all-cause
mortality.48-53 Frailty itself in the elderly HF population
is an independent predictor of emergency department
visits, hospitalizations and mortality.54,55 There is a close
link between frailty and comorbidities, polypharmacy
and malnutrition. Compounding the challenges of frailty
Review

among the elderly is cognitive impairment, ranging on
a spectrum of depression to fixed neurologic sequelae
from prior stroke and/or dementia (e.g. Alzheimer’s).
Since frailty appears to disproportionately affect the
elderly and has a greater influence on quality and quantity
of life, rational treatment options deliberated for elderly
patients with AHF must include its consideration. Frail
individuals have limited reserve for recovery from even
transient major physiologic insults such as major surgery,
prolonged intubation or intensive care time, hypoxia,
hypotension or metabolic derangements. Therefore, not
only will the frail patient be at greater risk from AHF
treatment interventions, but he or she also will have
reduced functional benefits with higher long-term adverse
outcomes. Hence, incumbent on an AHF treatment
program is deciphering which component of physical or
cognitive frailty is associated with the HF phenotype and
which is intrinsically related to the patient, as the former
would be treatable with AHF therapy options while the
latter may actually be made worse.
Frailty (cognitive or physical) is often much more
worrisome in patients receiving LVAD as destination
therapy, as this intervention is not easily rationed to
younger cohorts in whom frailty is less of a concern.
Neurocognitive dysfunction can negatively impact
overall well-being and QOL, and has been demonstrated
to pose a psychosocial burden on LVAD patients and
caregivers.56 A retrospective study of INTERMACS
conducted by Fendler et al. found that the risk of cognitive
decline in the first year following LVAD implantation
was greater with advanced age, particularly in patients
more than 70 years old.57 The study further noted that
the levels of cognitive decline after LVAD were greater
than levels seen in normal aging populations.57 Indeed,
another retrospective study58 examined outcomes in
LVAD patients undergoing destination therapy at Mayo
Clinic and found frailty was associated with a threefold
higher risk of mortality within 24 months postimplant.58
However, Flint et al. cautioned that the predictive value
of frailty in LVAD patients is complicated by the fact
that the underlying cardiac disease contributing to a
patient’s frailty may itself be reversed as a result of LVAD
therapy.48 Accordingly, recent studies have challenged
the traditional notion that age is a predictor of mortality
and adverse outcomes in patients who receive LVAD as
destination therapy34,59 and have suggested frailty may be
a superior metric in preoperative assessment.
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Personalized Care Model for AHF Therapy in
the Elderly
As previously stated, the incidence, prevalence,
morbidity, mortality and economic burden of HF
disproportionately affects those over age 70. With
improved treatment of acute cardiovascular diseases and
the aging worldwide population, an epidemic of HF is
anticipated over the next three decades. Unfortunately,
more elderly people with HF will ultimately translate
to a higher number of elderly people with AHF. Current
viable strategies for AHF include HT, LVAD and
palliative care, recognizing the latter should be part of
the decision tree for either of the first two options.
Over the last three decades, our institution has
performed more than 1,600 AHF surgical procedures
(870 HT and 745 LVAD), with outcomes exceeding
national benchmark standards. As advocated by many
peer-reviewed publications,27,28,60 center size, experience
and outcomes data should be factors when leveraging
AHF therapy options among nontraditional populations
of patients, including the elderly. Along with many other
large national programs,33 we have seen an increased
use of continuous-flow LVAD therapy as both bridge to
transplantation and destination therapy strategies as well
as the general aging of the patient population served with
these options. Our program’s relative age limit for HT is
70 years, and our percentage of transplants in this age
group mirrors national and international trends (less than
3%);23 notably, our institution has not performed HT in a
patient age 75 or older in more than a decade. Within the
last three years, roughly half of all LVADs implanted at
our program (n=152) have been for a destination therapy
indication, which calls for a multidisciplinary approach
to patient evaluation, selection, data collection and
reporting, and patient management. We employ several
measures in the evaluation of an LVAD candidate in the
context of assessing frailty. These include nutritional
parameters (10% unintentional weight loss, albumin and
prealbumin), physical assessment (hand grip, seated-torise time) and cognitive assessment (psychologic and
palliative). By developing and consistently employing
a multidisciplinary approach for all destination therapy
patients, we have shortened the time of evaluation and
decision (to a median of 12 days), reduced hospital length
of stay (to a median of 14 days post-LVAD surgery)
and improved clinical metrics and patient outcomes
including in-hospital, 6- and 24-month survival (94%,
84% and 68%, respectively).
www.aurora.org/jpcrr
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Central to the evaluation of a destination therapy
patient is an early referral for evaluation and caregiver
engagement. In addition to a team comprised of
experienced AHF-certified medical and surgical
cardiovascular specialists, all destination therapy patients
are evaluated by program-dedicated social workers,
pharmacists, psychologists, palliative care specialists,
nutritionists, financial coordinators, biomedical
engineers and nursing coordinators. Each professional
is expected to obtain precise information and provide
detailed education pertinent to his or her discipline.
Each discipline is charged with candidly presenting that
information during a weekly patient selection conference
in the context of written programmatic guidelines. The
goal of this process is to provide patients and families
with equitable evaluation and education regarding AHF
options and to define real and potential challenges to
successful patient outcomes.
If patients are accepted for AHF treatment (most
commonly LVAD as destination therapy) and elect to
pursue this option, then appropriate education of both
patient and caregivers is continued. Once patients
have undergone destination therapy LVAD for AHF,
we deploy the same multidisciplinary team to care for
them as they transition from intensive care to telemetry
step-down and eventually home. Once home, patients
are seen weekly in outpatient clinic for 4 weeks, during
which time a team comprised of an AHF provider,
AHF registered nurse, dedicated HF pharmacist
and a biomedical engineer optimizes medications,
anticoagulation, education and LVAD parameters,
taking into account patient symptoms. Postdischarge
care also includes education of emergency medical
services proximal to patient home location, structured
cardiac rehabilitation, measurement of QOL metrics
and monthly or quarterly clinic visits for ongoing
medical care. Once stable, patients without arrhythmia
are allowed to drive personal vehicles and return to
full activities such as travel, home care, sports and
recreation. Since our program mandates palliative care
consultation for all patients eligible for destination
therapy LVAD, we are able to seamlessly maintain
continuity of care once patients transition to a terminal
phase of illness while supported with LVAD therapy.
In our experience, if the patient is not frail (cognitively
or physically), has reasonable renal function
(chronic kidney disease stage 3 or less) and a stable
204 JPCRR • Volume 3, Issue 4 • Fall 2016

supportive psychosocial situation as determined by the
multidisciplinary team, then he or she would have the
best chance to benefit from placement of an LVAD.
Whether a comprehensive cost analysis of destination
therapy LVAD will prove to reduce intermediateterm costs remains to be seen; it is anticipated that
as complication rates and recurrent hospitalizations
among LVAD patients continue to fall and patient
selection improves, we may be able to curb health care
expenditures among elderly patients with AHF.
Conclusions
The current paradigm for AHF options among elderly
patients favors a broader application of LVAD as
destination therapy. While these technologies have
evolved from large pulsatile pumps with limited
durability to smaller, more durable devices, several
challenges need to be addressed in future device
designs. These challenges include LVAD-associated
gastrointestinal bleeding, stroke and driveline-associated
infections. The promise of novel magnetically levitated
pump designs, fewer moving parts with larger gaps for
blood to channel and fully implantable systems with
transcutaneous charging may help solve many of these
concerns. Regardless of anticipated advancements, the
central question should always remain: “For whom
should these technologies be applied?” We advocate the
development of robust multidisciplinary teams charged
with meticulously evaluating patients with AHF and
judiciously applying technologies for those who are
most likely to gain benefit.

Patient-Friendly Recap
• Advanced heart failure, the most severe stage
of heart failure, is more common among elderly
patients.
• The authors reviewed the reported success rates
of heart transplantation and LVAD therapy in this
population as well as palliative care alternatives.
• They concluded that choice of clinical action
must take into account patient-specific risks,
namely, the physical and mental conditions often
associated with aging.
•A
 dditionally, an established personalized model
of care for treating older patients with advanced
heart failure is described in detail.
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